anilides

Summary

Summary: Any aromatic amide obtained by acylation of aniline.

Top Publications

  1. Stanton B, Peng L. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst. 2010;6:44-54 pubmed publisher
    ..Several Shh inhibitors have not succeeded in the clinic for unknown reasons, but clinical trials in BCC and pancreatic cancer with the promising Smo antagonists GDC-0449 and IPI-926 are currently underway...
  2. Pratap A, Singh S, Mundra V, Yang N, Panakanti R, Eason J, et al. Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. J Drug Target. 2012;20:770-82 pubmed publisher
    ..Thus, GDC has the potential to serve as a new therapeutic agent for treating early liver fibrosis...
  3. Tiyerili V, Müller C, Fung S, Panek D, Nickenig G, Becher U. Estrogen improves vascular function via peroxisome-proliferator-activated-receptor-γ. J Mol Cell Cardiol. 2012;53:268-76 pubmed publisher
    ....
  4. Karlou M, Lu J, Wu G, Maity S, Tzelepi V, Navone N, et al. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate. 2012;72:1638-47 pubmed publisher
    ....
  5. Li C, Wu J, Hynes M, Dosch J, Sarkar B, Welling T, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011;141:2218-2227.e5 pubmed publisher
    ..c-Met is a marker of normal mouse pancreatic stem and progenitor cells; we investigated whether it is also a marker of human pancreatic CSCs that might be developed as a therapeutic target...
  6. Rudin C. Vismodegib. Clin Cancer Res. 2012;18:3218-22 pubmed publisher
    ..The mechanism of action, preclinical and clinical data, and potential utility in other disease contexts are reviewed here...
  7. Atwood S, Chang A, Oro A. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol. 2012;199:193-7 pubmed publisher
    ..Here, we summarize the effectiveness of Hedgehog pathway inhibitors and highlight promising areas for the development of next generation drug antagonists for Hedgehog-dependent cancers...
  8. Shiota A, Shimabukuro M, Fukuda D, Soeki T, Sato H, Uematsu E, et al. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice. Cardiovasc Diabetol. 2012;11:139 pubmed publisher
    ..Here, we investigated the pathways through which telmisartan acts on skeletal muscle, in vitro as well as in vivo...
  9. Smith D, Smith M, Sweeney C, Elfiky A, Logothetis C, Corn P, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31:412-9 pubmed publisher
    ..We evaluated the activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort...
  10. Tang J, Mackay Wiggan J, Aszterbaum M, Yauch R, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180-8 pubmed publisher
    ..Vismodegib is a new orally administered hedgehog-pathway inhibitor that produces objective responses in locally advanced and metastatic basal-cell carcinomas...

Detail Information

Publications62

  1. Stanton B, Peng L. Small-molecule modulators of the Sonic Hedgehog signaling pathway. Mol Biosyst. 2010;6:44-54 pubmed publisher
    ..Several Shh inhibitors have not succeeded in the clinic for unknown reasons, but clinical trials in BCC and pancreatic cancer with the promising Smo antagonists GDC-0449 and IPI-926 are currently underway...
  2. Pratap A, Singh S, Mundra V, Yang N, Panakanti R, Eason J, et al. Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. J Drug Target. 2012;20:770-82 pubmed publisher
    ..Thus, GDC has the potential to serve as a new therapeutic agent for treating early liver fibrosis...
  3. Tiyerili V, Müller C, Fung S, Panek D, Nickenig G, Becher U. Estrogen improves vascular function via peroxisome-proliferator-activated-receptor-γ. J Mol Cell Cardiol. 2012;53:268-76 pubmed publisher
    ....
  4. Karlou M, Lu J, Wu G, Maity S, Tzelepi V, Navone N, et al. Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b. Prostate. 2012;72:1638-47 pubmed publisher
    ....
  5. Li C, Wu J, Hynes M, Dosch J, Sarkar B, Welling T, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011;141:2218-2227.e5 pubmed publisher
    ..c-Met is a marker of normal mouse pancreatic stem and progenitor cells; we investigated whether it is also a marker of human pancreatic CSCs that might be developed as a therapeutic target...
  6. Rudin C. Vismodegib. Clin Cancer Res. 2012;18:3218-22 pubmed publisher
    ..The mechanism of action, preclinical and clinical data, and potential utility in other disease contexts are reviewed here...
  7. Atwood S, Chang A, Oro A. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol. 2012;199:193-7 pubmed publisher
    ..Here, we summarize the effectiveness of Hedgehog pathway inhibitors and highlight promising areas for the development of next generation drug antagonists for Hedgehog-dependent cancers...
  8. Shiota A, Shimabukuro M, Fukuda D, Soeki T, Sato H, Uematsu E, et al. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice. Cardiovasc Diabetol. 2012;11:139 pubmed publisher
    ..Here, we investigated the pathways through which telmisartan acts on skeletal muscle, in vitro as well as in vivo...
  9. Smith D, Smith M, Sweeney C, Elfiky A, Logothetis C, Corn P, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31:412-9 pubmed publisher
    ..We evaluated the activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort...
  10. Tang J, Mackay Wiggan J, Aszterbaum M, Yauch R, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180-8 pubmed publisher
    ..Vismodegib is a new orally administered hedgehog-pathway inhibitor that produces objective responses in locally advanced and metastatic basal-cell carcinomas...
  11. Kowdley K, Lawitz E, Poordad F, Cohen D, Nelson D, Zeuzem S, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370:222-32 pubmed publisher
    ....
  12. Feld J, Kowdley K, Coakley E, Sigal S, Nelson D, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-603 pubmed publisher
    ..In this phase 3 trial, we evaluated this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis...
  13. Poordad F, Hezode C, Trinh R, Kowdley K, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973-82 pubmed publisher
    ....
  14. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-92 pubmed publisher
    ..We conducted two phase 3 trials to examine the efficacy and safety of this regimen in previously untreated patients with HCV genotype 1 infection and no cirrhosis...
  15. Shi Y, Moura U, Opitz I, Soltermann A, Rehrauer H, Thies S, et al. Role of hedgehog signaling in malignant pleural mesothelioma. Clin Cancer Res. 2012;18:4646-56 pubmed publisher
    ..The aim of this study was to assess the activity of hedgehog signaling pathway in malignant pleural mesothelioma (MPM)...
  16. Lin T, Lee S, Niu Y, Xu D, Liang L, Li L, et al. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem. 2013;288:19359-69 pubmed publisher
    ..These findings suggest the potential risks of using anti-androgens and provide a potential new therapy using ASC-J9® to battle PCa metastasis at the castration-resistant stage. ..
  17. Kim J, Aftab B, Tang J, Kim D, Lee A, Rezaee M, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013;23:23-34 pubmed publisher
    ..Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMO(D477G) medulloblastoma...
  18. Zeng J, Aziz K, Chettiar S, Aftab B, Armour M, Gajula R, et al. Hedgehog pathway inhibition radiosensitizes non-small cell lung cancers. Int J Radiat Oncol Biol Phys. 2013;86:143-9 pubmed publisher
    ..Whether Hedgehog inhibition can affect radiation efficacy in vivo has not been reported...
  19. Sekulic A, Migden M, Oro A, Dirix L, Lewis K, Hainsworth J, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-9 pubmed publisher
    ..A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma...
  20. Qian F, ENGST S, Yamaguchi K, Yu P, Won K, Mock L, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009;69:8009-16 pubmed publisher
    ..Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors...
  21. Herrera C, Cranage M, McGowan I, Anton P, Shattock R. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob Agents Chemother. 2009;53:1797-807 pubmed publisher
    ..These findings may have important implications for the rational design of effective rectal microbicides...
  22. Ni M, Chen Y, Lim E, Wimberly H, Bailey S, Imai Y, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011;20:119-31 pubmed publisher
    ..Specific targeting of AR, Wnt or HER2 signaling impairs androgen-stimulated tumor cell growth suggesting potential therapeutic approaches for ER-/HER2+ breast cancers...
  23. Sennino B, Ishiguro Oonuma T, Wei Y, Naylor R, Williamson C, Bhagwandin V, et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012;2:270-87 pubmed publisher
    ..These findings document that invasion and metastasis are promoted by selective inhibition of VEGF signaling and can be reduced by the concurrent inhibition of c-Met...
  24. Quero L, Giocanti N, Hennequin C, Favaudon V. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells. Prostate. 2010;70:401-11 pubmed publisher
    ..However, biological data for the interaction between bicalutamide and ionizing radiation in concomitant association are lacking...
  25. Scales S, De Sauvage F. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci. 2009;30:303-12 pubmed publisher
    ..We review here the roles of the Hh pathway in cancer, Hh pathway inhibitors (HPIs) and early clinical trial results using a novel small molecule HPI, GDC-0449...
  26. Du J, Sun B, Chen K, Fan L, Wang Z. Antagonist of peroxisome proliferator-activated receptor gamma induces cerebellar amyloid-beta levels and motor dysfunction in APP/PS1 transgenic mice. Biochem Biophys Res Commun. 2009;384:357-61 pubmed publisher
    ..Since cerebellum is spared from significant Abeta accumulation and neurotoxicity in AD patients and animal models, these findings suggest a crucial role of PPARgamma steady-state activity in protection of cerebellum against AD pathology...
  27. Tran C, Ouk S, Clegg N, Chen Y, Watson P, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787-90 pubmed publisher
    ..These compounds thus appear to be promising candidates for treatment of advanced prostate cancer...
  28. Alonzi R, Padhani A, Taylor N, Collins D, d Arcy J, Stirling J, et al. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI. Int J Radiat Oncol Biol Phys. 2011;80:721-7 pubmed publisher
    ....
  29. Ventuneac A, Carballo Dieguez A, McGowan I, Dennis R, Adler A, Khanukhova E, et al. Acceptability of UC781 gel as a rectal microbicide among HIV-uninfected women and men. AIDS Behav. 2010;14:618-28 pubmed publisher
    ..Acceptability research is essential in early phases of microbicide development to identify potential problems, understand user preferences, and introduce changes if needed...
  30. Yauch R, Dijkgraaf G, Alicke B, Januario T, Ahn C, Holcomb T, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science. 2009;326:572-4 pubmed publisher
    ..These findings show that acquired mutations in a serpentine receptor with features of a G protein-coupled receptor can serve as a mechanism of drug resistance in human cancer...
  31. Von Hoff D, LoRusso P, Rudin C, Reddy J, Yauch R, Tibes R, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361:1164-72 pubmed publisher
    ..In a phase 1 clinical trial, we assessed the safety and pharmacokinetics of GDC-0449, a small-molecule inhibitor of SMO, and responses of metastatic or locally advanced basal-cell carcinoma to the drug...
  32. You W, Sennino B, Williamson C, Falcón B, Hashizume H, Yao L, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011;71:4758-68 pubmed publisher
    ....
  33. Philips G, Chan I, Swiderska M, Schroder V, Guy C, Karaca G, et al. Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer. PLoS ONE. 2011;6:e23943 pubmed publisher
    ..We used Mdr2(-/-) mice to investigate the hypothesis that activation of the hedgehog (Hh) signaling pathway promotes development of both liver fibrosis and HCC...
  34. Yakes F, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298-308 pubmed publisher
    ..Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling...
  35. Rudin C, Hann C, Laterra J, Yauch R, Callahan C, Fu L, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173-8 pubmed publisher
    ....
  36. Robarge K, Brunton S, Castanedo G, Cui Y, Dina M, Goldsmith R, et al. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009;19:5576-81 pubmed publisher
    ..5mg/kg BID in a medulloblastoma allograft mouse model that is wholly dependent on the Hh pathway for growth and is currently in human clinical trials, where it is initially being evaluated for the treatment of BCC...
  37. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009;69:6871-8 pubmed publisher
    ....
  38. Dijkgraaf G, Alicke B, Weinmann L, Januario T, West K, Modrusan Z, et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 2011;71:435-44 pubmed publisher
    ..Importantly, these HPI resistant MB allografts retained their sensitivity to PI3K inhibition, presenting additional opportunities for the treatment of such tumors...
  39. Yuan H, Kopelovich L, Yin Y, Lu J, Glazer R. Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti-estrogen therapy. Oncotarget. 2012;3:345-56 pubmed
    ..These findings suggest that it may be possible to pharmacologically influence the responsiveness of tumors to anti-estrogen therapy...
  40. Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci. 2011;102:51-6 pubmed publisher
    ....
  41. Eder J, Shapiro G, Appleman L, Zhu A, Miles D, Keer H, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16:3507-16 pubmed publisher
    ..Secondary objectives included evaluation of plasma pharmacokinetics, long-term safety after repeated administration, preliminary antitumor activity, and pharmacodynamic activity...
  42. Ng K, Chan A, Yu W. Pd-catalyzed intermolecular ortho-C-H amidation of anilides by N-nosyloxycarbamate. J Am Chem Soc. 2010;132:12862-4 pubmed publisher
    A palladium-catalyzed ortho-C-H amidation of anilides by N-nosyloxycarbamates was developed for the synthesis of 2-aminoanilines...
  43. Ishikura N, Kawata H, Nishimoto A, Nakamura R, Ishii N, Aoki Y. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10. Prostate. 2010;70:457-66 pubmed publisher
    ....
  44. Jin F, Fondell J. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression. Nucleic Acids Res. 2009;37:4826-38 pubmed publisher
    ..Collectively, our results suggest that Cdc6 is a key regulatory target for AR and provide new insights into the mechanisms of prostate cancer cell proliferation...
  45. Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate. 2010;70:745-54 pubmed publisher
    ..However, the mechanism of bicalutamide resistance remains unclear because few cell models have been generated...
  46. Kim S, Richardson M, Chinnakannu K, Bai V, Menon M, Barrack E, et al. Androgen receptor interacts with telomeric proteins in prostate cancer cells. J Biol Chem. 2010;285:10472-6 pubmed publisher
    ..Together, these observations suggest an allosteric role of AR in telomere complex stability in prostate cancer cells and suggest that AR-antagonist Casodex-mediated cell death may be due to telomere complex disruption...
  47. Liu L, Shi H, Liu Y, Anderson A, Peterson J, Greger J, et al. Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells. Mol Cancer Ther. 2011;10:518-30 pubmed publisher
    ..0225). These data suggest that combination therapy with foretinib and HER-targeted agents should be tested as a treatment option for HER1- or HER2-positive patients with MET-amplified or -overexpressing tumors...
  48. LoRusso P, Rudin C, Reddy J, Tibes R, Weiss G, Borad M, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res. 2011;17:2502-11 pubmed publisher
    ..This phase I trial assessed GDC-0449 treatment in patients with solid tumors refractory to current therapies or for which no standard therapy existed...
  49. Kurzrock R, Sherman S, Ball D, Forastiere A, Cohen R, Mehra R, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29:2660-6 pubmed publisher
    ..Early observations of clinical benefit in a phase I study of cabozantinib, which included patients with medullary thyroid cancer (MTC), led to expansion of an MTC-enriched cohort, which is the focus of this article...
  50. Thornton A, Zhao X, Weisleder N, Brotto L, Bougoin S, Nosek T, et al. Store-operated Ca(2+) entry (SOCE) contributes to normal skeletal muscle contractility in young but not in aged skeletal muscle. Aging (Albany NY). 2011;3:621-34 pubmed
    ....
  51. Zhu A, Li Y, Song W, Xu Y, Yang F, Zhang W, et al. Antiproliferative Effect of Androgen Receptor Inhibition in Mesenchymal Stem-Like Triple-Negative Breast Cancer. Cell Physiol Biochem. 2016;38:1003-14 pubmed publisher
    ..Previous studies have shown that AR is widely expressed in up to one-third of triple-negative breast cancer (TNBC). However, the role of AR in TNBC is still not fully understood, especially in mesenchymal stem-like (MSL) TNBC cells...
  52. Aloud B, Raj P, O Hara K, Shao Z, Yu L, Anderson H, et al. Conjugated linoleic acid prevents high glucose-induced hypertrophy and contractile dysfunction in adult rat cardiomyocytes. Nutr Res. 2016;36:134-42 pubmed publisher
    ....
  53. DeGoey D, Randolph J, Liu D, Pratt J, Hutchins C, Donner P, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem. 2014;57:2047-57 pubmed publisher
    ....
  54. Bogacka I, Bogacki M, Kurzynska A, Chojnowska K. The involvement of peroxisome proliferator activated receptors (PPARs) in prostaglandin F2α production by porcine endometrium. Reprod Biol. 2013;13:309-16 pubmed publisher
    ..The results indicate that PPARs are involved in the production of PGF2α by porcine endometrium, and that the sensitivity of the endometrium to PPAR ligands depends on reproductive status of animals...
  55. Oikonomou N, Mouratis M, Tzouvelekis A, Kaffe E, Valavanis C, Vilaras G, et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol. 2012;47:566-74 pubmed publisher
    ..Furthermore, the pharmacological inhibition of ATX attenuated the development of the modeled disease, suggesting that ATX is a possible therapeutic target in IPF...
  56. Metcalfe C, Alicke B, Crow A, Lamoureux M, Dijkgraaf G, Peale F, et al. PTEN loss mitigates the response of medulloblastoma to Hedgehog pathway inhibition. Cancer Res. 2013;73:7034-42 pubmed publisher
    ..Combined inhibition of the Hedgehog and PI3K pathways may lead to superior antitumor activity in PTEN-deficient medulloblastoma in the clinic...
  57. Cajaraville A, Lopez S, Varela J, Saa C. Rh(III)-catalyzed tandem C-H allylation and oxidative cyclization of anilides: a new entry to indoles. Org Lett. 2013;15:4576-9 pubmed publisher
    Rh(III)-catalyzed tandem C-H allylation and oxidative cyclization of anilides with allyl carbonates in the presence of a slight excess of AgSbF6 salt and Cu(OAc)2 as oxidant affords easy, economical access to important bioactive 2-..
  58. Dart D, Waxman J, Aboagye E, Bevan C. Visualising androgen receptor activity in male and female mice. PLoS ONE. 2013;8:e71694 pubmed publisher
    ..This model represents an important tool for physiological and developmental analysis of androgen signalling, and for characterization of known and novel androgenic or antiandrogenic compounds. ..
  59. Li S, Zhao Y, Wang K, Gao Y, Han J, Cui B, et al. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors. Bioorg Med Chem. 2013;21:2843-55 pubmed publisher
    ..In this study, a promising compound 33, with a c-Met IC50 value of 0.59 nM, was identified as a multitargeted receptor tyrosine kinase inhibitor...
  60. Sandbo N, Ngam C, Torr E, Kregel S, Kach J, Dulin N. Control of myofibroblast differentiation by microtubule dynamics through a regulated localization of mDia2. J Biol Chem. 2013;288:15466-73 pubmed publisher
    ....
  61. Badri P, Dutta S, Wang H, Podsadecki T, Polepally A, Khatri A, et al. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir. Antimicrob Agents Chemother. 2016;60:105-14 pubmed publisher
    ..Ketoconazole, digoxin, pravastatin, and rosuvastatin require lower doses, and omeprazole may require a higher dose. No dose adjustment is required for the 2D regimen...
  62. Shapiro G, McCallum S, Adams L, Sherman L, Weller S, Swann S, et al. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs. 2013;31:742-50 pubmed publisher
    ..003) and soluble VEGFR2 plasma levels significantly decreased from baseline (P<0.03). The MTD of foretinib bisphosphate salt was determined to be 80 mg once daily...